©The Author(s) 2025.
World J Gastroenterol. Dec 21, 2025; 31(47): 114377
Published online Dec 21, 2025. doi: 10.3748/wjg.v31.i47.114377
Published online Dec 21, 2025. doi: 10.3748/wjg.v31.i47.114377
Table 3 Eradication rate of Helicobacter pylori
| Dosage | 0.5 g-QID (95%CI) (%) | 0.75 g-QID (95%CI) (%) | 1 g-TID (95%CI) (%) | P value |
| ITT | 93.31 | 93.55 | 92.35 | 0.696 |
| 95%CI | 91.15-95.09 | 91.42-95.23 | 90.11-94.17 | |
| mITT | 95.67 | 95.21 | 95.16 | 0.911 |
| 95%CI | 93.84-96.98 | 93.33-96.55 | 93.27-96.51 | |
| PP | 97.43 | 97.11 | 96.90 | 0.870 |
| 95%CI | 95.73-98.46 | 95.35-98.21 | 95.09-98.05 |
- Citation: Wu CQ, Zhou X, Li CP, He QL, Chen ZH, Ding SB, Deng L, Chen LL, Jiang K, Dong CK, Hu L, Zhu GB, Zhang CG, Zhang Y, Wu LL, Li W, Mao YH, Zhang H, Ai X, He YQ, Ma Y, He SY. Regional multi-center randomized trial of three vonoprazan-amoxicillin dosing regimens for Helicobacter pylori eradication in Sichuan Province, China. World J Gastroenterol 2025; 31(47): 114377
- URL: https://www.wjgnet.com/1007-9327/full/v31/i47/114377.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i47.114377